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Elsevier Taiwan LLC. Open access under CSummary Hepatocellular carcinoma (HCC) is one of the most prevalent human cancers in the
world, but its prognosis is extremely poor. HCC is considered a hypervascular tumor. Thalido-
mide, which has been known to inhibit growth factor-induced neovascularization, is a conve-
nient alternative to target therapy such as sorafenib. We report a 65-year-old male patient
with alcoholic liver cirrhosis that was diagnosed having multiple HCCs during surveillance.
The patient was assessed as inoperable and unsuited for transhepatic arterial chemoemboliza-
tion or systemic chemotherapy. After discussing the therapeutic alternatives, he decided to
receive low-dose thalidomide (100 mg daily) therapy. Fortunately, follow-up liver biochemical
tests, serum a-fetoprotein level, and dynamic computed tomography showed complete remis-
sion of the HCCs 4.5 months after thalidomide treatment and this was documented for more
than 22 months without evidence of tumor recurrence.
Copyright ª 2014, The Gastroenterological Society of Taiwan and The Digestive Endoscopy So-
ciety of Taiwan. Published by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.Introduction
Hepatocellular carcinoma (HCC) is one of the most preva-
lent human cancers in the world, especially in Asia and
Africa, but its prognosis is extremely poor. Surgical resec-
tion and local radiofrequency ablation therapy are curative
in only a minority of patients and systemic chemotherapy is
difficult for HCC patients to tolerate because liver functionrch Unit, Chang Gung Memo-
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stroenterological Society of Taiw
C BY-NC-ND license.reserve is often impaired due to underlying cirrhosis, which
is accompanied by hypersplenism and peripheral cytopenia.
HCC is a relatively chemoresistant tumor and is highly re-
fractory to cytotoxic chemotherapy. Transhepatic arterial
chemoembolization (TACE) is the most widely used
locoregional treatment for patients with intermediate
stage HCC, but it is contraindicated in patients with main
portal vein thrombosis or poor liver function reserve. Sor-
afenib, an oral multikinase inhibitor that suppresses tumor
cell proliferation and angiogenesis, is the standard of care
for patients with advanced stage disease. However, sor-
afenib for advanced HCC is still not easy for Asian physi-
cians to prescribe due to high cost. Therefore, advanced
and unresectable HCC remains incurable, with a medianan and The Digestive Endoscopy Society of Taiwan. Published by
Advanced hepatocellular carcinoma 65survival of <6 months. Generally, HCC is considered a
hypervascular tumor. Increased levels of vascular endo-
thelial growth factor and high microvessel density have
been found in HCC. Therefore, inhibition of angiogenesis
represents a potential therapeutic target. Thalidomide,
which has been known to inhibit growth factor-induced
neovascularization, is a convenient alternative to treat-
ment with cytotoxic agents. We report a male patient with
alcoholic liver cirrhosis and advanced HCC after thalido-
mide treatment that achieved complete HCC remission.
Case report
A 65-year-old man was a victim of alcoholic liver cirrhosis
(ChildePugh class B) with ascites under diuretics (oral
furosemide 80 mg and spironolactone 200 mg daily) control
and received periodic HCC surveillance every 4 months for
14 years. Unfortunately, his a-fetoprotein (AFP) level was
highly elevated and abdominal ultrasonography detected
multiple liver tumors in November 2005. Physical exami-
nation revealed jaundice, mild hepatomegaly with a span
of 13 cm on the right middle clavicle line and an irregular
margin with a hard consistency that measured 2 cm below
the right costal margin. The spleen was impalpable. No
fever, skin rash, ascites, spider angioma, or palmar ery-
thema was noted. Laboratory studies disclosed the
following results: hemoglobin, 13.5 g/dL; leukocytes,
5.2  109/L; platelets, 110  109/L; albumin, 3.6 g/dL,
globulin, 3.1 g/dL; total bilirubin, 4.2 mg/dL (normal,
<1.3 mg/dL); serum aspartate aminotransferase (AST),
222 U/L (normal, <34 U/L); serum alanine aminotrans-
ferase (ALT), 51 U/L (normal, <36 U/L); alkaline phospha-
tase, 210 IU/L (normal, <94 IU/L); prothrombin time, 12.4
seconds (control, 10.0 seconds); international normalized
ratio, 1.12; and AFP 4935 ng/mL (normal < 3 ng/mL).
Hepatitis B surface antigen and antibody to hepatitis C virus
were both negative. Abdominal ultrasonography showed
multiple hyperechoic and mixed echoic tumors in cirrhotic
parenchyma, the largest being 5.9 cm in diameter, without
the presence of ascites. Dynamic computed tomography
(CT) showed multiple arterially enhanced tumors, mainly in
the right lobe having a portal- and delayed-phase washed-
out appearance. The invasion of tumors into the mainFigure 1 (A) Prior to thalidomide therapy, multiple arterially e
multiple infiltrating tumors were located in the central portion of th
4.5 months of thalidomide therapy showed complete remission of li
Follow-up examination after 20 months of thalidomide therapy showportal trunk and its proximal branches with suspicion of
biliary tree compression are shown in Fig. 1A. The tumors
were considered HCCs because of the presence of the
characterized arterial vascularization and rising AFP levels.
This patient appeared to be asymptomatic and was staged
as Barcelona Clinic Liver Cancer (BCLC) stage C.
The patient was assessed as inoperable and unsuited for
TACE or systemic chemotherapy. Attending a clinical trial
with target therapy was suggested initially, but the patient
refused. He agreed to receive thalidomide (50 mg capsule;
TTY Biopharm, Taipei, Taiwan) 50 mg twice daily after
obtaining written informed consent and followed at an
outpatient clinic. Three weeks after thalidomide therapy,
he occasionally complained of skin eruptions with itching.
There was no fever, nausea, constipation, vomiting, fa-
tigue, or somnolence. Laboratory studies disclosed the
following: AST, 436 U/L; ALT, 94 U/L; total bilirubin,
5.2 mg/dL; and serum AFP, 7350 ng/mL. He continued to
take thalidomide 100 mg daily without specific complaint.
Follow-up liver biochemical tests after 3 months of thalid-
omide therapy showed the following: AST, 44 IU/L; ALT,
29 IU/L; total bilirubin, 1.8 mg/dL; and serum AFP, 13 ng/
mL. The clinical course is shown in Fig. 2. Dynamic CT
showed significant regression of the portal vein thrombi and
complete remission of tumors 4.5 months after initial
diagnosis (Fig. 1B). Thalidomide dose was reduced to 50 mg
daily after 9 months treatment because of serum AFP and
ultrasonography showing no evidence of HCC recurrence.
Abdominal CT or ultrasonography at 20 months after
thalidomide therapy showed complete tumor regression
(Fig. 1C). The AST, ALT, and AFP levels remained within
normal limits. Unfortunately, he succumbed to a perforated
duodenal ulcer with multiple organ failure 22 months after
initial diagnosis.
Discussion
The clinical, laboratory, and image modalities on presen-
tation and the subsequent clinical course of this particular
patient indicated that he was a patient with HCC who
showed complete response to oral thalidomide therapy.
HCC is a highly prevalent disease in many Asian coun-
tries, accounting for 80% of victims worldwide. This patientnhanced tumors were located in the right lobe (arrow), and
e liver with portal vein thrombi. (B) Follow-up examination after
ver tumors and significant regression of portal vein thrombi. (C)
ed complete remission of liver tumors and portal vein thrombi.
Figure 2 Changes in serum a-fetoprotein (AFP) levels
before and after thalidomide therapy. ALT Z alanine
aminotransferase.
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and multiple HCCs (BCLC stage C). According to the Amer-
ican Association for the Study of Liver Diseases and the
European Association for the Study of the Liver guidelines,
only sorafenib is recommended for BCLC stage C HCC.
However, the treatment recommendation of the Asian Pa-
cific Association for the study of liver and Asian experts
disclosed not only sorafenib but also many therapeutic
options such as surgical resection, TACE, hepatic artery
infusion chemotherapy, and external radiation can be tried
for advanced stage [1]. Unfortunately, our patient had
impaired functional liver reserve and multinodular tumors
with portal vein invasion, and antiangiogenic treatment
was the favorable therapy. However, sorafenib was not
available in Taiwan in 2005. Thalidomide, an antiangio-
genesis agent, was found to have a modest effect in pa-
tients with advanced HCC. It is an alternative therapy in
patients with advanced HCC at a much lower cost than
sorafenib. Although the development of target agents
indeed represents an important advance in the treatment
of advanced HCC, studies of the efficacy of thalidomide are
less frequently reported [2].
Complete response to thalidomide therapy is rarely seen
in advanced HCC. Three phase II studies have evaluated the
utility of thalidomide in the treatment of advanced HCC
and demonstrated a response rate of 3e5% [3,4]; no patient
showed a complete response. To the best of our knowledge,
there were two patients with advanced HCC under thalid-
omide therapy who subsequently showed complete remis-
sion. In a retrospective study, one of 53 patients with
advanced HCC (1.9%) achieved a complete response; how-
ever, the patient had prior TACE [2]. In another report, the
complete response was observed in a 62-year-old man with
chronic hepatitis C and metastasis to multiple lymph nodes
and to the peritoneum [5]; he had received thalidomide
200e300 mg/day and had remained in a remission state for
more than 11 months. Demeria et al [6] administered
100 mg thalidomide once daily to a 73-year-old man with
multiple HCCs. Although a dramatic reduction in the tumor
size was seen after 1 month of therapy, he succumbed to
tumor recurrence 17 months after the initial diagnosis. In
our patient, complete remission of HCC was documentedfor a period of 22 months without evidence of tumor
recurrence.
Different dosages of thalidomide have been used in the
treatment of advanced HCC patients. It is well known that
thalidomide toxicity, but not necessarily efficacy, increases
with higher dosage. Chen et al [7] reported a patient whose
advanced HCC achieved durable remission after low-dose
thalidomide (50e100 mg) therapy. A retrospective study
also showed that for treating advanced HCC, low-dose
thalidomide (100 mg) has comparable single-agent activity
but less treatment-related toxicity compared to high-dose
thalidomide [8]. Our case demonstrates that a low dose
of thalidomide 50e100 mg daily can be effective for
treating advanced HCC and can even achieve a long-term
complete response.
Serum AFP levels are routinely monitored for tracking
post-treatment HCC recurrence. Alterations in serum AFP
levels have been shown to reflect accurately the response
of HCC to systemic chemotherapy and to TACE. Chen et al
[9] reported that AFP response can more accurately reflect
the biological response of advanced HCC to thalidomide
therapy than can radiographic response. In their series,
radiographic response was observed in all AFP responders.
AFP levels fell to nadir after 4e16 weeks (median 8 weeks)
of thalidomide therapy. Furthermore, early AFP response
(defined as decline > 20% from baseline after 2e4 weeks of
treatment) had better survival outcomes for patients with
advanced HCC who receive antiangiogenic therapy [10]. In
our case, a rapid fall of AFP after 8 weeks of therapy was
observed. Therefore, we suggest that the evaluation of the
therapeutic effect of therapy should incorporate AFP re-
sponses, especially in the early phase of treatment. If there
is early AFP response, low-dose thalidomide can be effec-
tive in patients with advanced HCC.
This patient with liver cirrhosis and advanced HCC under
low dose thalidomide therapy achieved complete remis-
sion. We suggest that thalidomide can be considered as an
alternative treatment in patients with advanced HCC, who
cannot afford sorafenib therapy.
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